Skip to content
Peptilyze
CompoundsShopsCompareMarketLab testsGuidesMethod

Nootropics · Reference article

Modafinil and sleep deprivation: what the trials show

Sleep-deprivation trials of modafinil in soldiers, pilots and shift workers: sizes, comparators, funding, how long benefits lasted and what was not tested.

Published · Updated · Rests on: 13 laboratory and flight trials, 5 shift-work trials, 1 shift-work guideline and review, 5 reviews, DoD report (2021), CRS brief (2025), FAA table (2026), FDA label, EMA referral

This is a reference article, not a price comparison. Peptilyze compares prices of research peptides; it sells nothing and gives no medical advice. Every claim is numbered and listed under Sources.

Key points

  • The evidence is mostly small laboratory trials from 1995 to 2012 in healthy adults kept awake for 37 to 85 hours. Against placebo, modafinil improved vigilance, alertness and mood for a few hours [1][6][11].
  • Where caffeine or dextroamphetamine were tested alongside it, simple vigilance gains were similar. One trial’s authors concluded modafinil had no advantage over caffeine [5][6].
  • Gains did not extend cleanly to judgement. Gambling-task decision-making stayed impaired on all three stimulants, one 64-hour trial found overconfidence, and a 2012 pilot trial found no significant flight-performance gain [3][10][13].
  • No trial we found measured accidents. Real-operations data are self-reports from pilots [16][17][30].
  • In shift workers, a 209-patient trial found a modest benefit and leftover sleepiness [18].

What kind of studies are these?

All are human adult studies: laboratory trials that keep healthy volunteers awake, simulator and flight trials with pilots, and shift-work trials in simulated night shifts or patients. This article reports what each found and gives no guidance on use. For approval, risks and the wider evidence see the complete guide, the caffeine comparison and the healthy adults evidence review.

Laboratory and flight trials, study by study

Study Size and time awake Measured Comparators Funding or drug supply Main result
Pigeau 1995, Canada-led [1] 41 military subjects, 64 h Mood, fatigue, sleepiness; reaction time, reasoning, memory Dextroamphetamine, placebo Grant from Laboratoire L. Lafon, the company that developed modafinil Both drugs beat placebo; analysis limited to 10 h after dosing; fewer side effects than amphetamine
Wesensten 2002, Walter Reed [5] 50 healthy adults, 54.5 h Performance, alertness Caffeine, placebo (10 per group) Cephalon supplied modafinil Comparable to caffeine, strongest 06:00-10:00; “does not appear to offer advantages over caffeine”
Wesensten 2005, Walter Reed [6] 48 adults, 85 h; drug at 64 h Psychomotor vigilance, alertness, executive tasks Caffeine, dextroamphetamine, placebo (12 each) No funding statement found in the full text All three equal for about 2-4 h; executive results mixed
Killgore 2008 [7] 53 adults, drug at 44 h Psychomotor vigilance Same three comparators Not opened All equally effective; duration shortest for caffeine, longest for dextroamphetamine
Caldwell 2000, US Army [11] 6 pilots, two 40 h periods Helicopter simulator, EEG, mood Placebo Cephalon supplied drug free of charge Better on 4 of 6 maneuvers; most benefit 03:30-11:30; vertigo, nausea, dizziness
Caldwell 2004, F-117 pilots [12] 10 F-117 pilots, 37 h Simulator, mood Placebo or no treatment, single-blind Not opened Better on 6 of 8 maneuvers, but did not sustain pre-deprivation performance
Estrada 2012, US Army [13] 18 helicopter pilots, two 40 h periods Real flights, vigilance, cognition, risk Dextroamphetamine, placebo US Special Operations Command and Army research command Mood and alertness better than placebo; flight performance not significantly better
Wingelaar-Jagt 2024, Netherlands [15] 32 air force personnel, about 17-25 h Vigilance, sleepiness Caffeine, placebo (crossover) None declared Both drugs improved most measures; groups of 10-11

Three patterns stand out. Benefits were short. Pigeau’s team limited analysis to 10 hours after each dose because little drug remained [1]. Wesensten’s trial put the shared benefit at 2-4 hours [6], and the Dutch field study reported peak effect 2-3 hours after use [16]. The largest gains came at the circadian low, the early-morning hours when sleep loss and body clock coincide [5][11]. And modafinil was not shown better than caffeine or dextroamphetamine on simple vigilance, and on planning tasks each drug won on a different task [6][9].

Estrada’s result deserves care. The abstract says modafinil kept judgement and situation awareness “consistently better than placebo”. The paper’s discussion says flight performance was not significantly better in either drug group, and cognitive tests showed no significant drug effect. Placebo reaction times were slower in the sleep-deprived periods. The authors suggested flights of 35 to 40 minutes were too short to show fatigue differences [13].

Studies in shift workers

  • Czeisler 2005 randomised 209 patients with shift-work sleep disorder for three months. Nighttime sleep latency improved by 1.7 minutes on modafinil versus 0.3 on placebo, 74% versus 36% had clinical improvement, and fewer reported accidents or near-accidents commuting home (29% versus 54%). Patients “continued to have excessive sleepiness and impaired performance at night” [18]. We could not open the funding statement.
  • Walsh 2004 gave 32 volunteers modafinil or placebo across four simulated night shifts. Alertness, vigilance and three executive tasks improved; subjective sleepiness did not consistently differ [19]. PubMed lists a NIOSH grant; we did not open the full text.
  • Hart 2006 (11 participants, 23 days) and Grady 2010 (18 participants, a 25-day forced-desynchrony protocol) found less night-shift or prolonged-wake impairment on modafinil. Both list NIH grants in PubMed [20][21].
  • Gill 2006 tested emergency physicians after night shifts in a crossover design. Some attention measures improved, and falling asleep got harder when sleep was possible [22].
  • A 2021 review of night-float interventions for trainee doctors found five studies, 179 participants, and low or very low certainty evidence [25].
  • The American Academy of Sleep Medicine’s guideline (24 October 2026) suggests modafinil or armodafinil for excessive sleepiness in adults with shift work disorder, a conditional recommendation with moderate certainty. Its caffeine recommendations were conditional with very low certainty. The supporting review drew on 118 studies with analysable data [23][24].

Reviews and meta-analyses

The American Academy of Sleep Medicine task force (2005) concluded modafinil improved psychomotor performance, alertness and mood during sleep loss of up to 85 hours versus placebo, noting some studies lacked full statistics [26]. Wesensten’s 2006 review called for more head-to-head comparisons [27]. Repantis (2010) pooled data and found modafinil maintained wakefulness, memory and executive function in sleep-deprived people, but repeated doses could not prevent decline over longer deprivation [28]. A military meta-analysis (2012) found only three eligible studies, all in rested adults [29]. We found no meta-analysis restricted to sleep-deprivation trials; our search was not exhaustive. A 2025 systematic review of military-pilot fatigue countermeasures included seven studies and reported no accident or incident outcomes [30].

What the trials did not show

Recovery sleep. Results conflict. Wesensten found no drug effect on recovery sleep, with performance back at baseline afterwards [6]; Killgore found no harm to post-recovery performance [7]. Buguet reported smaller recovery-sleep need in the modafinil group of the 64-hour trial [2], while the AASM task force concluded modafinil, like other stimulants, “does not reduce sleep need” and may delay recovery sleep [26]. Performance returned to pre-deprivation levels after recovery sleep in all groups [6], which is a return to normal, not a lasting benefit.

Judgement and overconfidence. Baranski and Pigeau (1997) found modafinil produced “overconfidence” in self-rated performance, most marked 2-4 hours after dosing, while placebo and amphetamine groups judged themselves largely accurately [3]. A driving-simulator study of 16 people found lane-keeping gains but possible overconfidence [14]. Baranski’s 2004 follow-up in 18 rested adults found good calibration on trial-by-trial judgements and a non-significant tendency at task level [4]. Estrada’s pilots showed no differences among conditions on risk measures [13]. Killgore’s 54-volunteer gambling-task study found decision-making stayed impaired on all stimulants, returning to normal after recovery sleep [10]. A related risk-taking study found dextroamphetamine restored risk propensity, with modafinil not differing from it [8]. Evidence on judgement is thin and inconsistent.

Real operations. Caldwell’s team wanted side effects reduced before aviator use [11]. A Dutch field study of 75 pilots cleared in ground tests recorded 192 operational flights; pilots reported positive effects in 182 and no sleep problems afterwards, but all outcomes were self-reported [16]. A survey of 29 F-15E aircrew over 111 combat sorties linked stimulant use (drug types not separated in the abstract) to lower fatigue [17]. None measured crashes or errors.

How military and aviation authorities describe it

  • United States Department of Defense, report to Congress, 26 February 2021: dextroamphetamine is approved under a flight surgeon in the Army, Navy, Air Force and Marine Corps; modafinil is approved in the Air Force depending on Major Command guidance. It calls the stimulants “safe and effective” in combat or emergencies under strict guidelines, but a last resort after rest options are exhausted. It cites an Air Force instruction (AFI 48-149, 2014), which we did not open [32].
  • Congressional Research Service, updated 13 May 2025: no DoD-wide policy exists; each service sets its own; use is voluntary; Air Force policy allows modafinil [33].
  • FAA, Do Not Issue table updated 30 September 2026: “Stimulants” appear among drugs AMEs cannot issue a medical for without FAA clearance. Modafinil is not named, and we could not verify how the FAA classes it [34].
  • A 2021 review says the air forces of Singapore, India and France approved modafinil [31]; we did not verify this in official documents. UK, Canada, Germany, Netherlands: not verified.

Regulatory status

Checked 8 November 2026: the US label (revised February 2025) covers excessive sleepiness in narcolepsy, obstructive sleep apnea and shift work disorder, lists Schedule IV, and says it “is not a replacement for sleep” [35]. In the EU, the Commission decision of 27 January 2011 restricted use to narcolepsy [36]. UK and German status were not re-checked here; see the complete guide. Sleep-deprivation use in healthy people is off-label. As a prescription medicine, “research use only” does not apply.

Risks and unknowns

Side effects in these trials included vertigo, nausea and dizziness in pilots, headache in shift-work patients, and harder sleep onset [11][18][22]. Serious skin, psychiatric and contraceptive-interaction warnings are in the complete guide. Not studied: accident outcomes, use beyond a few weeks in healthy people, and older adults (most samples were young).

Frequently asked questions

Does modafinil replace sleep?

No trial shows that. The US label says it “is not a replacement for sleep” [35]. In the trials, performance improved for hours, then sleep debt still had to be paid [6][26].

Is modafinil better than caffeine under sleep deprivation?

In two Walter Reed trials and a Dutch crossover trial, they were broadly similar on vigilance, though each did better on different tasks and the measures that reached significance differed [5][6][9][15]. Side effects and duration of action also differed [7].

Do the trials show modafinil is safe in real operations?

No. Field data are self-reported and no trial measured accidents. The DoD report calls such drugs a last resort [16][30][32].

Does it work for shift workers?

A 209-patient trial found a modest improvement, but patients stayed sleepy. The 2026 AASM guideline gives a conditional recommendation [18][23].

Sources

  1. Pigeau R et al., “Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work. I”, J Sleep Res 1995;4:212-28. https://pubmed.ncbi.nlm.nih.gov/10607161/ (funding line read in a mirror copy of the paper).
  2. Buguet A et al., “… II. Effects on two nights of recovery sleep”, J Sleep Res 1995 (Dec). https://pubmed.ncbi.nlm.nih.gov/10607162/
  3. Baranski JV, Pigeau RA, “Self-monitoring cognitive performance during sleep deprivation”, J Sleep Res 1997;6:84-91. https://pubmed.ncbi.nlm.nih.gov/9377538/
  4. Baranski JV et al., “Effects of modafinil on cognitive and meta-cognitive performance”, Hum Psychopharmacol 2004;19:323-32. https://pubmed.ncbi.nlm.nih.gov/15252824/
  5. Wesensten NJ et al., “Maintaining alertness and performance during sleep deprivation: modafinil versus caffeine”, Psychopharmacology 2002;159:238-47. https://pubmed.ncbi.nlm.nih.gov/11862356/ (acknowledgements read in a mirror copy).
  6. Wesensten NJ et al., J Sleep Res 2005;14:255-66. https://pubmed.ncbi.nlm.nih.gov/16120100/ (full text read in a mirror copy).
  7. Killgore WD et al., “Effects of dextroamphetamine, caffeine and modafinil on psychomotor vigilance test performance after 44 h of continuous wakefulness”, J Sleep Res 2008;17:309-21. https://pubmed.ncbi.nlm.nih.gov/18522689/
  8. Killgore WD et al., “Restoration of risk-propensity during sleep deprivation”, Aviat Space Environ Med 2008;79:867-74. https://pubmed.ncbi.nlm.nih.gov/18785355/
  9. Killgore WD et al., “Sustaining executive functions during sleep deprivation”, Sleep 2009;32:205-16. https://pubmed.ncbi.nlm.nih.gov/19238808/
  10. Killgore WD et al., “Gambling when sleep deprived: don’t bet on stimulants”, Chronobiol Int 2012;29:43-54. https://pubmed.ncbi.nlm.nih.gov/22217100/
  11. Caldwell JA et al., “A double-blind, placebo-controlled investigation of the efficacy of modafinil for sustaining the alertness and performance of aviators”, Psychopharmacology (Berl) 2000 (Jun). https://pubmed.ncbi.nlm.nih.gov/10923755/ (acknowledgements read in a mirror copy).
  12. Caldwell JA et al., “Modafinil’s effects on simulator performance and mood in pilots during 37 h without sleep”, Aviat Space Environ Med 2004;75:777-84. https://pubmed.ncbi.nlm.nih.gov/15460629/
  13. Estrada A et al., “Modafinil as a replacement for dextroamphetamine for sustaining alertness in military helicopter pilots”, Aviat Space Environ Med 2012;83:556-64. https://pubmed.ncbi.nlm.nih.gov/22764609/ (full text read in a mirror copy).
  14. Gurtman CG et al., “Effects of modafinil on simulator driving and self-assessment of driving following sleep deprivation”, Hum Psychopharmacol 2008;23:681-92. https://pubmed.ncbi.nlm.nih.gov/19039821/
  15. Wingelaar-Jagt YQ et al., “Comparison of effects of modafinil and caffeine on fatigue-vulnerable and fatigue-resistant aircrew”, Front Physiol, published 8 Jan 2024. https://www.frontiersin.org/articles/10.3389/fphys.2023.1303758/full
  16. Wingelaar-Jagt YQ et al., “Subjective effects of modafinil in military fighter pilots during deployment”, Aerosp Med Hum Perform 2022;93(10):739-45. https://pubmed.ncbi.nlm.nih.gov/36243913/
  17. Gore RK et al., “Fatigue and stimulant use in military fighter aircrew during combat operations”, Aviat Space Environ Med 2010;81:719-27. https://pubmed.ncbi.nlm.nih.gov/20681231/
  18. Czeisler CA et al., “Modafinil for excessive sleepiness associated with shift-work sleep disorder”, N Engl J Med 2005;353:476-86. https://pubmed.ncbi.nlm.nih.gov/16079371/
  19. Walsh JK et al., “Modafinil improves alertness, vigilance, and executive function during simulated night shifts”, Sleep 2004;27:434-9. https://pubmed.ncbi.nlm.nih.gov/15164895/
  20. Hart CL et al., “Modafinil attenuates disruptions in cognitive performance during simulated night-shift work”, Neuropsychopharmacology 2006;31:1526-36. https://pubmed.ncbi.nlm.nih.gov/16395298/
  21. Grady S et al., Neuropsychopharmacology 2010;35:1910-20. https://pubmed.ncbi.nlm.nih.gov/20505660/
  22. Gill M et al., “Cognitive performance following modafinil versus placebo in sleep-deprived emergency physicians”, Acad Emerg Med 2006;13:158-65. https://pubmed.ncbi.nlm.nih.gov/16436796/
  23. Wright KP et al., “Management of shift work disorder: an AASM clinical practice guideline”, J Clin Sleep Med (24 Oct 2026). https://pubmed.ncbi.nlm.nih.gov/42925456/
  24. Wright KP et al., “Management of shift work disorder: an AASM systematic review, meta-analysis, and GRADE assessment”, J Clin Sleep Med (24 Oct 2026). https://pubmed.ncbi.nlm.nih.gov/42925443/
  25. Sholtes D et al., “Optimising sleep and performance during night float”, J Sleep Res 2021;30:e13212. https://pubmed.ncbi.nlm.nih.gov/33058426/
  26. Bonnet MH et al., “The use of stimulants to modify performance during sleep loss”, Sleep 2005;28:1163-87. https://pubmed.ncbi.nlm.nih.gov/16268386/ (full text read in a mirror copy).
  27. Wesensten NJ, “Effects of modafinil on cognitive performance and alertness during sleep deprivation”, Curr Pharm Des 2006;12:2457-71. https://pubmed.ncbi.nlm.nih.gov/16842170/
  28. Repantis D et al., Pharmacol Res 2010;62:187-206. https://pubmed.ncbi.nlm.nih.gov/20416377/
  29. Kelley AM et al., “Cognition enhancement by modafinil: a meta-analysis”, Aviat Space Environ Med 2012;83:685-90. https://pubmed.ncbi.nlm.nih.gov/22779312/
  30. Alzahrani AA et al., “Efficacy of Fatigue Countermeasures on Cognitive Performance and Operational Safety in Military Pilots: A Systematic Review”, Cureus, 31 Oct 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12665280/
  31. Wingelaar-Jagt YQ et al., “Fatigue in Aviation: Safety Risks, Preventive Strategies and Pharmacological Interventions”, Front Physiol 2021;12:712628 (6 Sep 2021). https://pmc.ncbi.nlm.nih.gov/articles/PMC8451537/ (first 100,000 characters read).
  32. US Department of Defense (Under Secretary for Personnel and Readiness), “Study on Effects of Sleep Deprivation on Readiness of Members of the Armed Forces: Final Report” (26 Feb 2021). https://health.mil/Reference-Center/Reports/2021/02/26/Study-on-Effects-of-Sleep-Deprivation-on-Readiness-of-Members-of-the-Armed-Forces-Final-Report
  33. Congressional Research Service, “Management of Sleep and Fatigue in Military Aviation”, IF11881 v5 (updated 13 May 2025). https://www.congress.gov/crs_external_products/IF/PDF/IF11881/IF11881.5.pdf
  34. FAA, “Do Not Issue - Do Not Fly” tables (updated 30 Sep 2026). https://www.faa.gov/ame_guide/media/DNI_DNF_tables.pdf
  35. Apotex Corp., “PROVIGIL prescribing information”, DailyMed (revised 2/2025). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0391f182-1958-9fef-a944-53b229ce99e7
  36. EMA, “Modafinil - referral” (CHMP 18 Nov 2010; Commission decision 27 Jan 2011). https://www.ema.europa.eu/en/medicines/human/referrals/modafinil

This article is information, not medical advice.

More in Nootropics